Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Allogeneic Human Mesenchymal Stem Cells (HMSC) Infusions in Patients With Mild to Moderate Alzheimer's Disease
NCT04040348Phase 1Completed
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Alzheimer's disease (AD). Primary endpoint: Treatment-Emergent Serious Adverse Events. Started Oct 2019; status: completed.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04040348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040348.